---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216731"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-05-11T20:05:17+00:00"
generated_at: "2026-05-11T22:53:13.220840+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028

## Summary
- Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.
- Positive combo data with enzalutamide: median rPFS 7.0 mo overall, 10.1 mo in 1 prior ARPI.
- Pivotal Phase 3 protocol for roxadustat in LR-MDS being finalized after FDA feedback; trial start H2 2026.
- Revenue $3.7M (up from $2.7M); net loss $15.1M vs $16.8M YoY.
- Cash and equivalents $100.3M; sufficient to fund operations into 2028.

## SEC filing metadata
- accession: 0001193125-26-216731
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-05-11T20:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/0001193125-26-216731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216731
- JSON: https://secwatch.observer/filing/0001193125-26-216731.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216731.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported first quarter 2026 results: revenue $3.7 million, net income $15.1 million, or $3.74 net loss per basic and diluted share, EPS $3.74 net loss per basic and diluted share.
  - Period: first quarter 2026
  - Revenue: $3.7 million
  - Net income: $15.1 million, or $3.74 net loss per basic and diluted share
  - EPS: $3.74 net loss per basic and diluted share
  - Result: reported results
  source text: Total revenue from continuing operations for the first quarter of 2026 was $3.7 million, as compared to $2.7 million for the first quarter of 2025. • Net loss from continuing operations for the first quarter of 2026 was $15.1 million, or $3.74 net loss per basic and diluted share, compared to a net loss of $16.8 million, or $4.15 net loss per basic and diluted share, one year ago.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/0001193125-26-216731-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.